Efficacy and Safety of Baricitinib in Neuromyelitis Optica Spectrum Disorders — Stella

Clinical trial discovery in plain English. Data sourced from ClinicalTrials.gov.

ClinicalTrials.gov ↗

Stella is not a medical provider and does not give medical advice. AI-generated summaries are for informational purposes only. Always consult your doctor before making any healthcare decisions.

Efficacy and Safety of Baricitinib in Neuromyelitis Optica Spectrum Disorders — Stella

Recruiting

Back to NMO Spectrum Disorder trials

Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.

Trial locations(1 site)

China

Tianjin Medical University General Hospital, Tianjin, Tianjin Municipality

Key details

Phase

Early testing / Safety & dosing

Sponsor

Tianjin Medical University General Hospital

Collaborators

Tang-Du Hospital, The Second Hospital of Shandong University

Enrollment target

~12 participants

Started

April 2023

Primary completion

December 2025

This trial's estimated completion date has passed — the record may not be fully up to date.

Age range

18 Years – 85 Years

Last updated October 2024

Interested in joining?

Tell us you're interested and we'll help connect you with the research team. We'll never share your email without your permission.

Your name

Email address

Follow this trial

Get notified in plain English when this trial's status changes. No account required.

View full record on ClinicalTrials.gov